WP5 JA1 Pilot Pazopanib Report+Appendix
The final version of the WP5 JA1 pilot assessment using the draft model for Rapid Relative Effectiveness Assessment of Pharmaceuticals and guidelines. The joint assessment involved the participation of 22 HTA organisations as authors on different domains or as reviewers. Find the full list on page 16 in side the report. The final version of the WP5 […]
Public consultation of the Methodological Guidelines for Rapid Relative Effectiveness Assessment of Pharmaceuticals
This document presents the public consultation of WP5 Joint Action Methodological Guidelines for Rapid Relative Effectiveness Assessment of Pharmaceuticals. The Methodological Guidelines for Rapid Relative Effectiveness Assessment of Pharmaceuticals under production by Work Package 5 Joint Action 1 were open for public consultation during the following periods: 29 June – 10 September 2012 […]
Methodological guideline for REA of pharmaceuticals: Composite endpoints
This guideline provides a set of recommendations for the selection and assessment of clinical endpoints when completing a Relative Effectiveness Assessment (REA) of pharmaceuticals. A composite endpoint (CE) consists of two or more single events combined in one outcome that should represent an overall clinically relevant and valid measure of clinical benefit due to treatment. […]
Methodological guideline for REA of pharmaceuticals: Internal validity
This guideline focuses on the assessment of the risk of bias of randomized controlled trials (RCTs), the most relevant trials for relative effectiveness assessment (REA) of pharmaceuticals. The quality assessment of non-randomized and diagnostic accuracy studies will be elaborated in separate guidelines. Likewise, a separate guideline deals with the problem of assessing applicability. Internal validity describes […]
Methodological guideline for REA of pharmaceuticals: Applicability of evidence in the context of a REA
This guideline provides a set of recommendations and aspects to be considered for the assessment of applicability in the context of a relative effectiveness assessment. Applicability, also known as external validity/ generalisability/ or transposability, is the extent to which the effects observed in clinical studies are likely to reflect the expected results when a specific […]
List of comments for the WP5 JA1 Pilot Pazopanib Report
The list of comments for the WP5 JA1 Pilot Pazopanib Report. The list provides the contact information of all the organisations that properly submitted their contributions. The list of comments for the WP5 JA1 Pilot Pazopanib Report. The list provides the contact information of all the organisations that properly submitted their contributions. This document is […]
List of commentators for the WP5 JA1 Pilot Pazopanib Report
The list with commentators provides the contact information of all the organisations that properly submitted contributions. The list with commentators provides the contact information of all the organisations that properly submitted contributions. List of commentators for the WP5 JA1 Pilot Pazopanib Report
A new application of the HTA Core Model – the HTA Core Model for Rapid Relative Effectiveness Assessment of pharmaceuticals
The HTA Core Model defines the content elements to be considered in a health technology assessment (HTA) and facilitates standardised reporting. The aim is to share information, to avoid duplication of work, and to facilitate the adaptation of information in national HTA reports and the co-production of HTA reports (by multiple HTA agencies). Detailed information […]
Methodological guideline for REA of pharmaceuticals: Direct and indirect comparison
To make the best use of available evidence on the efficacy of a treatment, it is common to combine results from several randomised controlled trials (RCTs) in a meta-analysis. This guideline focuses on the methods available for treatment comparisons. Their strengths and limitations are discussed and recommendations are provided in order to support Relative Effectiveness […]
Methodological guideline for REA of pharmaceuticals: Criteria for the choice of the most appropriate comparator(s)
This document provides a summary of current national policies and best practice recommendations for HTA assessors for selecting the most appropriate comparator for relative effectiveness assessments. The comparator in a relative effectiveness assessment (REA) is a health care intervention or other technology with which a pharmaceutical is compared in order to establish if it has […]
